ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 97 filers reported holding ALX ONCOLOGY HLDGS INC in Q1 2022. The put-call ratio across all filers is 0.84 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $51,830 | -33.7% | 10,798 | +3.7% | 0.00% | – |
| Q2 2023 | $78,202 | +67.1% | 10,413 | +0.6% | 0.00% | – |
| Q1 2023 | $46,796 | -59.1% | 10,353 | +2.0% | 0.00% | -100.0% |
| Q4 2022 | $114,357 | +17.9% | 10,147 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $97,000 | +19.8% | 10,184 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $81,000 | -45.6% | 10,040 | +14.1% | 0.00% | 0.0% |
| Q1 2022 | $149,000 | -26.2% | 8,803 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $202,000 | -71.8% | 9,422 | -2.9% | 0.00% | -75.0% |
| Q3 2021 | $717,000 | +32.0% | 9,705 | -2.3% | 0.00% | +100.0% |
| Q2 2021 | $543,000 | -27.6% | 9,935 | -2.3% | 0.00% | -33.3% |
| Q1 2021 | $750,000 | +53.7% | 10,168 | +79.6% | 0.00% | +50.0% |
| Q4 2020 | $488,000 | +125.9% | 5,660 | -1.1% | 0.00% | +100.0% |
| Q3 2020 | $216,000 | – | 5,724 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $46,559,640 | 13.20% |
| Vivo Capital, LLC | 4,220,048 | $20,256,230 | 2.22% |
| Logos Global Management LP | 1,000,000 | $4,800,000 | 0.64% |
| Orbimed Advisors | 2,871,000 | $13,780,800 | 0.29% |
| Redmile Group, LLC | 1,283,289 | $6,159,787 | 0.29% |
| BRAIDWELL LP | 1,249,900 | $5,999,520 | 0.19% |
| Cormorant Asset Management, LP | 612,079 | $2,937,979 | 0.17% |
| Nan Fung Group Holdings Ltd | 41,950 | $201,360 | 0.16% |
| Forefront Analytics, LLC | 13,769 | $66,092 | 0.04% |
| CORNERCAP INVESTMENT COUNSEL INC | 35,071 | $168,341 | 0.03% |